Extract
From the authors:L. Guglielmetti and co-workers acknowledge that methods used by the World Health Organization (WHO) to develop guidance have improved policies on multidrug-resistant tuberculosis (MDR-TB) in recent years. However, they express some concerns about the interpretation and communication of evidence in the 2019 WHO consolidated guidelines for drug-resistant TB treatment [1].
Abstract
WHO MDR-TB treatment guidelines detail how evidence and other considerations are used to develop recommendations http://bit.ly/35qSrZT
Footnotes
Author contributions: D. Falzon developed a first draft of the manuscript and the other authors proposed revisions towards its finalization. All authors agreed with the version submitted for publication. D. Falzon, T. Kasaeva, F. Mirzayev and M. Zignol are staff members of the World Health Organization (WHO). They alone are responsible for the views expressed in this publication and they do not necessarily represent the decisions or policies of WHO. The designations used and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area, or of its authorities, nor concerning the delimitation of its frontiers or boundaries.
Conflict of interest: D. Falzon has nothing to disclose.
Conflict of interest: H.J. Schünemann declares that his employer (McMaster University) received funding from WHO related to work he carries out on guideline development on tuberculosis. He has also received consultancy fees from WHO for work unrelated to tuberculosis.
Conflict of interest: M. Zignol has nothing to disclose.
Conflict of interest: F. Mirzayev has nothing to disclose.
Conflict of interest: T. Kasaeva has nothing to disclose.
- Received December 4, 2019.
- Accepted December 11, 2019.
- The content of this work is copyright of the authors or their employers. Design and branding are copyright ©ERS 2020.